21.10
6.03%
+1.20
(After Hours:
21.47
+0.37
+1.75%)
May-05-22 12:50PM | Veracyte, Inc. 2022 Q1 - Results - Earnings Call PresentationSeeking Alpha |
May-04-22 03:18AM | Analyst Ratings for VeracyteBenzinga |
Apr-08-22 06:50AM | Is This Under-the-Radar Growth Stock a Buy?The Motley Fool |
Mar-01-22 06:48AM | 10 Biggest Price Target Changes For TuesdayBenzinga |
Feb-24-22 07:40AM | Inogen (INGN) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research |
Feb-09-22 03:01AM | Will Veracyte (VCYT) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research |
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
List of SPAC Stocks
List of EV Stocks and Related Stocks
Top 100 popular stocks on Robinhood
List of Marijuana Stocks
Cap:
|
Volume (24h):